期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 470, 期 1-2, 页码 151-157出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2014.04.053
关键词
Avastin; PEG hydrogel; Corneal neovascularization; Sustained release
资金
- Natural Science Foundation of China [NSFC51303136]
- Specialized Research Fund for the Doctoral Program of Higher Education [20133321120001]
- Zhejiang Provincial Natural Science Foundation [Y2080992]
Avastin (R) has been clinically proved to be effective in the treatment of intraocular neovascularization diseases. However, the short half-life of Avastin (R) need frequent administration to maintain its therapeutic efficiency. In this paper, we attempted to develop an in situ PEG hydrogels with great biocompatibility for sustained release of Avastin (R) to inhibit the corneal neovascularization. PEG hydrogels was formed via thiol-maleimide reaction using 4-arm PEG-Mal and 4-arm PEG-SH. The transparent hydrogel was rapidly formed under physiological conditions. By varying the concentration of 4-arm PEG-SH, PEG hydrogel with different gelling time, pore size, swelling ratio and mechanical property could be obtained. In vitro cytotoxicity indicated that the developed PEG hydrogel had no apparent cytotoxicity on L-929 cells after 7 days of incubation. In vitro release study showed the encapsulated Avastin (R) was sustained release from PEG hydrogels within a period of 14 days study. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis further confirmed that the released Avastin (R) did not undergo apparent hydrolysis within 14 days. As a conclusion, we could conclude that the developed PEG hydrogels as an injectable hydrogels might be suitable for extended Avastin (R) release to treat the corneal neovascularization. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据